14 January 2021

T 1627/18 - RNA delivery

 Key points

  • This case is interesting mostly because of the technology at issue.
    • Namely "a liposome for in vivo delivery of RNA to a vertebrate cell, ... [comprising] RNA which encodes an immunogen".
  • Claim 1 of the patent reads as follows: "A liposome for in vivo delivery of RNA to a vertebrate cell, the liposome having a lipid bilayer encapsulating an aqueous core, wherein:
    (i) the lipid bilayer comprises a lipid having a pKa in the range of 5.0 to 6.8 when measured as described in the section "pKa measurement" of the description; and
    (ii) the aqueous core includes a RNA which encodes an immunogen."
  • The opposition was withdrawn in the cours of the appeal of the patentee. The Board finds claim 1 to be novel, unlike the OD, and remits the case to the OD to decide whether to continue the proceedings of own motion pursuant to Rule 84(2) EPC.


EPO T 1627/18 - link 

(decision text omitted)

No comments:

Post a Comment

Do not use hyperlinks in comment text or user name. Comments are welcome, even though they are strictly moderated (no politics). Moderation can take some time.